Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909219 | 0.87 | ALDH1A1 (0.52) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL22030506 | 0.84 | ALDH1A1 (0.49) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL22891662 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL18909253 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL24521453 | 0.82 | ALDH1A1 (0.54) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL17285967 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL22030928 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL18023792 | 0.80 | ALDH1A1 (0.45) | ALDH1A1PKMKDM4E | |
| SCHEMBL17286057 | 0.80 | ALDH1A1 (0.45) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL29325496 | 0.78 | CHRM5 (0.48) | ALDH1A1PKMTHRBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3416967-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180354959-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-12-13 | — | — | US | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | ALDH1A1 1817/4885CACNA2D1 4612/4885CACNA1B 3703/4885 |
| US-20180354959-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 1804/4885CACNA2D1 4398/4885CACNA1B 3873/4885 |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 1817/4885CACNA2D1 4612/4885CACNA1B 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.